Skip to main content

Author: Bill Snyder

VUMC team puts tool to reduce heart failure admissions to test

Nov. 11, 2021—Vanderbilt researchers have developed a risk stratification tool to predict outcomes and avoid unnecessary hospital admissions after emergency department visits for acute heart failure.

Read more


New way to bEET insulin resistance

Nov. 11, 2021—Signaling molecules called EETs could improve insulin resistance, a primary risk factor for Type 2 diabetes and cardiovascular disease, Vanderbilt researchers have discovered.

Read more


Translational Research Forum honors scientific excellence

Nov. 11, 2021—Vanderbilt University Medical Center’s strength in translational research, which helps “translate” scientific discovery into medical practice, was celebrated recently during the Vanderbilt Translational Research Forum

Read more


Zost honored for research on COVID-19, other life-threatening viral diseases

Oct. 28, 2021—Vanderbilt's Seth Zost, PhD, has been awarded a major international prize for his research on COVID-19 and other life-threatening viral diseases. 

Read more


Nominations being accepted for 2022 Vanderbilt Prize

Oct. 18, 2021—Nominations for the 2022 Vanderbilt Prize in Biomedical Science are now being accepted.

Read more


New marker for metaplasia

Oct. 14, 2021—A protein that transports water, called aquaporin 5, is expressed by cells undergoing changes that may increase risk for gastric cancer development, Vanderbilt researchers discovered.

Read more


STAR Clinical Research Network to receive major grant renewal

Oct. 14, 2021—Vanderbilt's STAR Clinical Research Network has been approved for an additional $8.9 million in funding from the Patient-Centered Outcomes Research Institute (PCORI) to support its efforts to improve health care throughout the Southeast and across the United States.

Read more


AstraZeneca seeks emergency approval for COVID-19 antibodies isolated at VUMC

Oct. 5, 2021—Biopharmaceutical company AstraZeneca has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration for a long-acting antibody combination originally developed at Vanderbilt University Medical Center to protect against COVID-19.

Read more


VUMC research contributed to first COVID-19 pill now under review

Oct. 1, 2021—Vanderbilt research helped allow pharmaceutical giant Merck & Co. to authorization for the first oral antiviral pill to treat COVID-19.

Read more


Neurotransmitter transporters expert Amara set for Oct. 7 Discovery Lecture

Sep. 29, 2021—Susan Amara, PhD, scientific director of the Intramural Research Program at the NIMH and an expert on the biology of neurotransmitter transporters, will deliver Vanderbilt's next Discovery Lecture via Zoom at 4 p.m., Thursday, Oct. 7.

Read more


“Ultra-potent” antibody against COVID-19 variants isolated at VUMC

Sep. 22, 2021—A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.

Read more


VUMC team to test personalized acute heart failure treatment

Sep. 16, 2021—Researchers at Vanderbilt have been awarded a five-year, $4 million federal grant to test whether a personalized medicine strategy will improve outcomes for patients hospitalized with acute heart failure.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more